Longevity, wealth governance, and the future of finance are colliding in 2026—and most people aren’t prepared.

As life expectancy rises and healthspans extend, individuals and institutions are being forced to rethink everything from retirement timelines to intergenerational wealth strategies. Longevity is no longer just a medical topic—it’s a systemic financial risk and opportunity.

This episode breaks down the emerging longevity economy, where innovations like telomere testing, anti-aging biotech, and concierge medicine are merging with advanced financial planning. We explore how family offices and private capital are adapting—deploying strategies to preserve wealth across longer lifecycles while investing in the very technologies driving human lifespan expansion.

From personalized health optimization to multi-generational capital allocation, this deep dive reveals how the future will be shaped by those who can align biology, finance, and long-term strategy.

TIMESTAMPS

00:00 Introduction to longevity and wealth

03:10 Why longer lifespans change everything

06:40 Longevity as a financial risk

10:20 The rise of longevity planning

14:00 Healthspan vs lifespan explained

17:30 Telomere testing and biological aging

21:00 Anti-aging biotechnology trends
longevity economy 2026, wealth governance strategy, extended lifespan finance, 100 year life planning, family office investment strategy, anti aging biotech investing, telomere testing explained, concierge medicine trends, healthspan vs lifespan, intergenerational wealth planning, private capital longevity, biotech investment trends, future of retirement planning, long term wealth preservation, longevity risk finance, health optimization technology

#Longevity #Wealth #Investing #Finance #Biotech #Future #Health #FamilyOffice #Economy #Strategy